

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/657,811
Filing Date	September 8, 2003
First Named Inventor	Mark Ledeboer
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	VPI/02-121 US

				U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
						i.	
					:		

				FOREIGN PATENT DOCUMENTS	:	
Exam Initials	Cite No.	Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
ESO	Bl	wo	01/12621	Vertex Pharamceuticals Incorporated	22 February 2001	
					7	

·	•	OTHER NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
ESO	CI	Bozyczko-Coyne, D., et al., "Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease," Curr Drug Targets - CNS and Neurological Disorders, 1(1):31-49 (2002).
<u> </u>	<u>. </u>	,
	ļ	<u> </u>
ļ	 	1
-		

* a copy of this reference is not provided as it was previously	y cited by or submitted to the office in a prior application,
U.S.S.N, filed	, and relied upon for an earlier filing date under 35 U.S.C. §120
(continuation, continuation-in-part, and divisional application	ons).

Examine Signatur	/Eric Olson/	Date Considered	08/03/2006	
	1			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.